Six Months In: A 2026 Progress Check on Pharma Dealmaking, Access and Commercialization

As the pharmaceutical industry crosses the midpoint of 2026, the landscape is defined by an accelerating dealmaking environment, fast-moving shifts in how patients access and pay for therapies and a widening gap in patient affordability. Concluding its H1 Review/H2 Outlook series, Pharmaceutical Commerce checked back in with four experts spanning M&A, direct-to-patient commercialization, patient access and commercial strategy to see how the forecasts they made earlier this year have held up, and what’s to come in H2.